Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

Fig. 2

A Correlation between SETD2 deleterious mutations and TMB. The difference of TMB in patients with SETD2 deleterious mutations and non-deleterious mutations across different cancer types in the GenePlus cohort. B Difference of tumor mutation burden (TMB) in patients with diverse molecular features (SETD2 deleterious mutations, BRCA1/2 deleterious mutations, MMR genes deleterious mutations, or POLE/D1 deleterious mutations) from the GenePlus cohort (Wilcoxon rank-sum test; ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05.)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us